Haemonetics (HAE) Gross Profit (2009 - 2026)

Haemonetics' Gross Profit history runs 18 years deep, the most recent figure standing at $198.2 million for Q1 2026.

• On a quarterly basis, Gross Profit rose 2.67% year-over-year to $198.2 million in Q1 2026; TTM through Mar 2026 was $787.6 million, a 5.16% increase from a year earlier, with the FY2026 full-year figure at $787.6 million, up 5.16% from the prior year.
• Gross Profit declined to $198.2 million in Q1 2026 per HAE's latest filing, from $202.4 million in the prior quarter.
• Across five years, Gross Profit topped out at $202.4 million in Q4 2025 and bottomed at $136.3 million in Q2 2022.
• The 5-year median for Gross Profit is $175.4 million (2024), against an average of $173.2 million.
• Across the five-year window, Gross Profit surged 66.63% in 2022 and climbed 2.67% in 2026, its largest moves.
• Year by year, Gross Profit stood at $158.7 million in 2022, then rose by 12.07% to $177.9 million in 2023, then climbed by 8.82% to $193.5 million in 2024, then advanced by 4.57% to $202.4 million in 2025, then slipped by 2.06% to $198.2 million in 2026.
• Per Business Quant, the three latest HAE Gross Profit figures stand at $198.2 million (Q1 2026), $202.4 million (Q4 2025), and $194.7 million (Q3 2025).